MAPT and Alzheimer disease: Trial eligibility includes a diagnosis of probable AD dementia or prodromal AD, evidence of the AD pathological process as confirmed by CSF tau/ Aβ42 or amyloid PET scan, and demonstrated abnormal memory function.